GKOS (Glaukos) Shareholder Yield % : 0.32% (As of Mar. 2026)


GKOS Glaukos Corp GKOS
80 GF Score
Price $142.30
GF Value $135.47
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Glaukos Shareholder Yield %?

Glaukos GKOS -0.19% 80 Shareholder Yield % is 0.32% as of Mar. 2026. GuruFocus rates GKOS with a GF Score™ of 80/100 and a GF Value™ of $135.47 (Fairly Valued). The stock has 6 warning signs investors should review. Among 817 Medical Devices & Instruments companies, Glaukos ranks better than 52.39% on this metric.

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return. As of today, Glaukos's Shareholder Yield % was 0.32%.


Glaukos  (NYSE:GKOS) Shareholder Yield % Explanation

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."

Shareholder Yield % is calculated by three components: Dividend Yield %, Buyback Yield %, and Net Debt Paydown Yield %.

Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.

Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.


Glaukos Shareholder Yield % Related Terms


Glaukos Shareholder Yield % Historical Data

* Premium members only.

The historical data trend for Glaukos's Shareholder Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Glaukos Shareholder Yield % Chart

Glaukos Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shareholder Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.55 -0.39 -0.03 2.17 1.47

Glaukos Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shareholder Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.53 3.54 3.54 1.47 0.42

GKOS vs LIVN, BIO, IRTC: Shareholder Yield % Comparison

For the Medical Devices subindustry, Glaukos's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Glaukos Shareholder Yield % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Glaukos's Shareholder Yield % distribution charts can be found below:

* The bar in red indicates where Glaukos's Shareholder Yield % falls into.


GKOS
80GF Score
Glaukos Corp GKOS
Shareholder Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Glaukos Shareholder Yield % Calculation

Glaukos's Shareholder Yield % for the quarter that ended in Mar. 2026 is calculated as:

Shareholder Yield %=Dividend Yield %+Buyback Yield %+Net Debt Paydown Yield %
=0.00 %+0.00 %+0.42 %
=0.42 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.

Frequently Asked Questions Learn more about Shareholder Yield % →
What does a Shareholder Yield % of 0.32% mean?
Glaukos (GKOS) has a Shareholder Yield % of 0.32% as of Mar. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Glaukos and its competitors. According to the industry distribution chart, Glaukos ranks #389 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 47.6%.
Is Glaukos' Shareholder Yield % too high?
Glaukos' current Shareholder Yield % is 0.32%. The Medical Devices & Instruments industry median Shareholder Yield % is 0.14. Glaukos' value of 0.32% is 128.6% above this industry median. Based on the distribution chart, Glaukos ranks #389 out of 817 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Glaukos has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Glaukos' Shareholder Yield % compare to LIVN and BIO?
According to the Medical Devices & Instruments industry distribution chart, Glaukos ranks #389 out of 817 companies for Shareholder Yield %. This puts Glaukos in the upper half of its industry. The industry median Shareholder Yield % is 0.14. Glaukos' value of 0.32% is 128.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Medical Devices & Instruments company?
The median Shareholder Yield % among Medical Devices & Instruments companies is 0.14, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Shareholder Yield % significantly above this median, while those in the bottom quartile fall well below. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Glaukos's current Shareholder Yield % of 0.32% is 128.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Glaukos and its competitors. For the Medical Devices & Instruments industry, the median Shareholder Yield % is 0.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Glaukos's current Shareholder Yield % is 0.32%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glaukos stock overvalued right now?
Based on GuruFocus' analysis, Glaukos (GKOS) is currently considered Fairly Valued. The stock's GF Value™ is $135.47, compared to a current price of $142.30 — trading 5% above its estimated fair value. The current Shareholder Yield % is 0.32% and 128.6% above the Medical Devices & Instruments industry median of 0.14. Glaukos' overall GF Score™ is 80/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Glaukos (GKOS), the current Shareholder Yield % is 0.32% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Glaukos (GKOS) Overvalued in 2026?

Based on GuruFocus' analysis, Glaukos stock appears to be overvalued. The current stock price of $142.30 is trading 5% above its estimated GF Value™ of $135.47. GuruFocus considers Glaukos to be Fairly Valued.

Key valuation signals for GKOS:

  • Shareholder Yield %: 0.32%
  • GF Value™: $135.47 vs. price of $142.30 (5% above fair value)
  • GF Score™: 80/100 with 6 warning signs
  • Industry Position: 128.6% above the Medical Devices & Instruments median (#389 of 817)

No single metric tells the full story. See the GKOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Glaukos Business Description

Other Exchanges 6GJ:Germany
Address One Glaukos Way, Aliso Viejo, CA, USA, 92656
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
80GF Score

Get the complete analysis for GKOS

Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$142.30
Price
$135.47
GF Value